Patient Education and Partnership Informed decisions lead to the best outcomes
Point32Health, along with a number of other insurers, have limited coverage of GLP-1s largely to people with diabetes, and it seems there has been at least some financial recovery
[DOI] [PMC free article] [PubMed] [Google Scholar] 84.Bagh M.B., Maiti A.K., Jana S., Banerjee K., Roy A., Chakrabarti S
Men and women of all ages in the Marlboro, NJ area choose physician-led GLP-1 therapy because sustainable weight loss requires more than convenience
The more recent SELECT trial, published in the New England Journal of Medicine in 2023 and highlighted by the American Heart Association, showed a 20% reduction in major cardiovascular events in patients with overweight or obesity and pre-existing cardiovascular disease but without diabetes